Wednesday, April 17, 2019 3:50:49 PM
Bijal D. Shah, MD
Published: Tuesday, Apr 16, 2019
Don`t let the shorts shake you out, that`s teri game!!!!
Watch this new video:https://www.onclive.com/onclive-tv/dr-shah-on-overcoming-resistance-to-btk-inhibitors-in-mcl
Bijal D. Shah, MD, associate member, Department of Malignant Hematology, Moffitt Cancer Center, discusses overcoming resistance to BTK inhibitors in mantle cell lymphoma (MCL).
Ibrutinib (Imbruvica) and acalabrutinib (Calquence) are both FDA approved for patients with relapsed/refractory MCL, but it is not standard practice to give these agents consecutively. This is due in large part to the overlapping mechanisms that drive resistance to these BTK inhibitors, says Shah. Moreover, mutations like p53 tend to create a more aggressive disease, limiting physicians’ ability to salvage with another BTK inhibitor.
Ongoing research is looking at whether an alternative method of blocking the B-cell receptor can overcome resistance to BTK inhibition. For example, an ongoing trial is looking at the combination of duvelisib (Copiktra), a PI3K gamma and delta inhibitor, and the BCL-2 inhibitor venetoclax (Venclexta). The hope is that the combination can attack the B-cell receptor from a different angle, and in doing so indicate whether the downstream mutations are as pivotal in cancer proliferation as believed to be.
Recent VSTM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:30:17 PM
- Verastem Oncology to Present at the 2024 Cantor Global Healthcare Conference • Business Wire • 09/10/2024 08:05:00 PM
- Verastem Oncology to Present Mature RAMP 201 Data in Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society 2024 Annual Meeting • Business Wire • 09/10/2024 11:30:00 AM
- Verastem Oncology and STAAR Ovarian Cancer Foundation Establish the Inaugural Low-Grade Serous Ovarian Cancer (LGSOC) Awareness Day on September 9, 2024 • Business Wire • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:42 PM
- Verastem Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 08/08/2024 08:05:00 PM
- Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer • Business Wire • 07/29/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/24/2024 09:06:01 PM
- Verastem Oncology Announces Pricing of $55.0 Million Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/24/2024 03:20:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/23/2024 08:33:23 PM
- Verastem Oncology Announces Proposed Public Offering of Common Stock, Warrants and Pre-Funded Warrants • Business Wire • 07/23/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:01:17 PM
- Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics • Business Wire • 07/12/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 11:00:18 AM
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 07/08/2024 11:30:00 AM
- Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes • Business Wire • 07/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 11:01:58 AM
- Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer • Business Wire • 05/24/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 09:24:02 PM
- Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer • Business Wire • 05/23/2024 09:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:08:56 PM
- Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates • Business Wire • 05/09/2024 08:02:00 PM
- Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference • Business Wire • 05/07/2024 11:30:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM